Follicular Lymphoma · line 3 · Tazemetostat 800 mg PO BID continuous — r/r FL (EZH2-mut OR EZH2-WT after ≥2 lines)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	3
Track	standard
Linked regimen	`REG-TAZEMETOSTAT-FL`

ID	`IND-FL-3L-TAZEMETOSTAT`
Type	Indication
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	`DIS-FL`
Sources	`SRC-ESMO-LYMPHOMA-2025` `SRC-NCCN-BCELL-2025`

Notes

STUB — pending Co-Lead sign-off. Standard-track 3L+ option for r/r FL. EZH2-mut subset enrichment is prefer-but-not-required. Oral administration and low toxicity profile make this the preferred choice for older / frail patients ineligible for parenteral salvage. UA access barrier dominant.

Used By

Algorithms

ALGO-FL-2L - ALGO-FL-2L